Longo C, Pampena R, Lallas A, et al. Adjuvant therapy for
cutaneous melanoma: a systematic review and network
meta-analysis of new therapies....
Podlipnik S, Carrera C, Boada A, et al. Early outcome of a 31-
gene expression profile test in 86 AJCC stage IB-II melanoma
patients. A prospective...
Dummer R, Hauschild A, Santinami M, et al. Five-year analysis
of adjuvant dabrafenib plus trametinib in stage III melanoma.
N Eng J Med. 2020;383(12):1139–1148....
Eggermont AMM, Blank CU, Mandala M, et al. Longer followup confirms recurrence-free survival benefit of adjuvant
pembrolizumab in high-risk...
Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant
nivolumab versus ipilimumab in resected stage IIIB-C and
stage IV melanoma (CheckMate...
Kelly ZR, Gorantla VC, Davar D. The role of neoadjuvant
therapy in melanoma. Curr Oncol Rep. 2020;22(8):80. https://doi.
org/10.1007/s11912-020-00944-5.
Lee AY, Brady MS. Neoadjuvant immunotherapy for melanoma. J Surg Oncol. 2021;123(3):782–788. https://doi.org/10.
1002/jso.26229.
Asaoka M, Gandhi S, Ishikawa T, Takabe K. Neoadjuvant
chemotherapy for breast cancer: past, present, and future.
Breast Cancer (Auckl). 2020....
Tetzlaff MT, Messina JL, Stein JE, et al. Pathological assessment of resection specimens after neoadjuvant therapy for
metastatic melanoma....
Tetzlaff MT, Adhikari C, Lo S, et al. Histopathological features
of complete pathological response predict recurrence-free
survival following...
Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus
adjuvant ipilimumab plus nivolumab in macroscopic stage III
melanoma. Nat Med....
Long GV, Saw RPM, Lo S, et al. Neoadjuvant dabrafenib
combined with trametinib for resectable, stage IIIB-C, BRAF
(V600) mutation-positive...
Rozeman EA, Menzies AM, Van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab...
Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune
checkpoint blockade in high-risk resectable melanoma. Nat
Med. 2018;24(11):1649–1654....
Rozeman EA, Reijers ILM, Hoefsmit EP, et al. Twenty-four
months RFS and updated toxicity data from OpACIN-neo: a
study to identify the optimal...
Recruiting, Active, Not Recruiting Studies | Melanoma - List
Results - ClinicalTrials.gov. [Acceso 21 Enero 2021]. Disponible en:
https://clinicaltrials.gov/ct2/results?term=neoadjuvant&cond=
melanoma&Search=Apply&recrs=a&recrs=d&age_v=&gndr=
&type=&rslt=.
Moreno-Ramírez D, Vieira R, Kaufmann R. Surgical approach
to patients with low-burden stage III melanoma: is it time to
consider conservative...
Faries MB, Thompson JF, Cochran AJ, et al. Completion
dissection or observation for sentinel-node metastasis in
melanoma. N Eng J Med. 2017;376(23):2211–2222....
Leiter U, Stadler R, Mauch C, et al. Final analysis of DeCOG-SLT
trial: no survival benefit for complete lymph node dissection
in patients...
Schermers B, Franke V, Rozeman EA, et al. Surgical removal of
the index node marked using magnetic seed localization to
assess response to...
Blank CU, Reijers ILM, Pennington T, et al. First safety and
efficacy results of PRADO: a phase II study of personalized
response-driven surgery...
